NeurOp Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 6

NeurOp General Information

Description

Developer of medicines designed to treat central nervous system disorders. The company develops medicines for central nervous system disorders, including severe pain, subarachnoid hemorrhage, and catastrophic juvenile epilepsies, and its technology targets the subunit of neuronal receptors and their potential therapeutic benefit, enabling patients to treat their pain, stroke, hemorrhage, and treatment-resistant depression.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 58 Edgewood Avenue, North East
  • 1st Floor, Suite 122
  • Atlanta, GA 30303
  • United States
+1 (404)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • 58 Edgewood Avenue, North East
  • 1st Floor, Suite 122
  • Atlanta, GA 30303
  • United States
+1 (404)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeurOp Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Secondary Transaction - Private 01-Apr-2021 Completed Clinical Trials - Phase 1
13. Grant 04-Feb-2019 Completed Clinical Trials - Phase 1
12. Later Stage VC Cancelled Clinical Trials - Phase 1
11. Grant 01-Jul-2017 Completed Clinical Trials - Phase 1
10. Grant 29-Sep-2014 Completed Clinical Trials - General
9. Seed Round 17-Feb-2014 Completed Clinical Trials - General
8. Grant 15-Apr-2013 Completed Clinical Trials - General
7. Grant 06-Sep-2012 Completed Clinical Trials - General
6. Grant 01-Jan-2011 $3.67M $635K Completed Clinical Trials - General
5. Angel (individual) 01-Jan-2011 $135K $635K Completed Clinical Trials - General
To view NeurOp’s complete valuation and funding history, request access »

NeurOp Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of medicines designed to treat central nervous system disorders. The company develops medicines for central ne
Drug Discovery
Atlanta, GA
6 As of 2025

Raritan, NJ
 

Lexington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NeurOp Competitors (23)

One of NeurOp’s 23 competitors is Johnson&Johnson Innovative Medicine, a Venture Capital-Backed company based in Raritan, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Johnson&Johnson Innovative Medicine Venture Capital-Backed Raritan, NJ
Voyager Therapeutics Formerly VC-backed Lexington, MA
Cognition Therapeutics Formerly VC-backed New York, NY
Achelios Therapeutics Venture Capital-Backed Durham, NC
Gilead Formerly VC-backed Foster City, CA
You’re viewing 5 of 23 competitors. Get the full list »

NeurOp Patents

NeurOp Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022339672-A1 Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph Active 02-Sep-2021
AU-2022339672-B2 Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph Active 02-Sep-2021
CA-3230601-A1 Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph Pending 02-Sep-2021
EP-4395783-A1 Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph Pending 02-Sep-2021
EP-4395783-A4 Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph Pending 02-Sep-2021 C07D295/135
To view NeurOp’s complete patent history, request access »

NeurOp Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NeurOp Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Institutes of Neurological Disorders and Stroke Government
Bristol-Myers Squibb Corporation Minority
Georgia Research Alliance Not-For-Profit Venture Capital Minority
Advanced Technology Development Center Accelerator/Incubator Minority
Ariel Savannah Angel Partners Angel Group Minority
You’re viewing 5 of 6 investors. Get the full list »

NeurOp FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process